Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma (EOXP)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Massachusetts General Hospital.
Recruitment status was  Recruiting
Information provided by:
Massachusetts General Hospital Identifier:
First received: April 24, 2008
Last updated: May 3, 2010
Last verified: May 2010

A pilot study to determine the safety of using perioperative panitumumab with EOX in patients with adenocarcinoma of the esophagus and stomach.

Condition Intervention Phase
Esophageal Adenocarcinoma
Gastric Adenocarcinoma
Drug: panitumumab, epirubicin, oxaliplatin, xeloda
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pilot Study of Perioperative Panitumumab in Combination With Epirubicin, Oxaliplatin and Xeloda in Patients With Resectable Gastroesophageal Adenocarcinoma

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • The safety of adding panitumumab to the perioperative regimen of EOX [ Time Frame: 1-2 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 30
Study Start Date: April 2008
Estimated Study Completion Date: April 2011
Estimated Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Pilot study
Drug: panitumumab, epirubicin, oxaliplatin, xeloda
pilot study


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed diagnosis of adenocarcinoma of the stomach, gastroesophageal junction, or lower third of the esophagus, AJCC stage II-IIIB (gastric) or IIA-IVA (esophageal). M1a disease will be included, but not T4 lesions.
  • No prior radiation or chemotherapy including anti-EGFR or vascular endothelial growth factor (VEGF) antibody or tyrosine kinase inhibitor treatments.
  • All patients must have staging endoscopic ultrasound (EUS) prior to enrollment.
  • Men or Women >18 years of Age
  • ECOG performance status <2 (Karnofsky >60%, see Appendix A).
  • Cardiac ejection fraction >45% by echocardiogram or MUGA scan.
  • Must be able to either swallow pills or have gastrostomy tube in place for administration of enteral medications.
  • Patients must have normal organ, metabolic and marrow function as defined below:

    • Hematologic function, as follows:

      • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
      • Platelet count ≥ 100 x 109/L
      • Hemoglobin ≥ 9.0 g/dL
    • Renal function, as follows:

      • Creatinine < or = 1.5 mg/dL x ULN

Hepatic function, as follows:

  • Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT)< or = 3 x ULN
  • Total bilirubin < 1.5 x ULN

Metabolic function, as follows:

  • Magnesium ≥ lower limit of normal
  • Calcium < or = lower limit of normal -Human IgG is known to cross the placental barrier; therefore, Panitumumab may be transmitted from the mother to the developing fetus. In women of childbearing potential, appropriate contraceptive measures must be used during treatment with panitumumab and for 6 months following the last dose of panitumumab. If panitumumab is used during pregnancy or if the patient becomes pregnant while receiving this drug, she should be apprised of the potential risk for loss of the pregnancy or potential hazard to the fetus.

3.1.10 Ability to understand and the willingness to sign and date a written IEC/IRB approved informed consent form.

Exclusion Criteria:

  • Evidence of distant metastatic disease.
  • T4 tumor on initial staging studies.
  • History of another primary cancer, except:
  • Curatively treated in situ cervical cancer
  • Curatively resected non-melanoma skin cancer
  • Other primary solid tumor curatively treated with no known active disease present and no treatment administered for ³ 5 years prior to enrollment
  • Relative or absolute contraindications to surgery which in the opinion of the investigator make the patient a poor candidate for surgical resection.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to panitumumab or other agents used in study.
  • Subjects requiring chronic use of immunosuppressive agents (e.g., methotrexate, cyclosporine).
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or any evidence of interstitial lung disease on baseline chest CT scan.
  • History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risks associated with the study participation or investigational product(s) administration or may interfere with the interpretation of the results.
  • Subject unwilling or unable to comply with study requirements.
  • Women who test positive for serum or urine pregnancy test < 72 hours before randomization or are breast feeding.
  • Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection.
  • Major surgery with 28 days or minor surgery within 14 days of study enrollment.
  • Men or women of child-bearing potential (women who are post-menopausal < 52 weeks, not surgically sterilized, or not abstinent) not consenting to use adequate contraception (per institutional standard of care) during the course of the study and after the last investigational product(s) administration (24 weeks for women, 4 weeks for men).
  • Subjects with > grade 1 neuropathy at baseline.
  • Contraindication to port-a-cath placement.
  Contacts and Locations
Please refer to this study by its identifier: NCT00667420

Contact: David P Ryan, MD 617-724-0245

United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Principal Investigator: David P Ryan, MD         
DFCI Recruiting
Boston, Massachusetts, United States, 02115
Contact: Petet Enzinger, MD         
Principal Investigator: Peter Enzinger, MD         
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: David P Ryan, MD Massachusetts General Hospital
  More Information

No publications provided

Responsible Party: David Ryan MD, Massachusetts General Hospital Identifier: NCT00667420     History of Changes
Other Study ID Numbers: 07326
Study First Received: April 24, 2008
Last Updated: May 3, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Massachusetts General Hospital:

Additional relevant MeSH terms:
Stomach Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Antibodies, Monoclonal
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs processed this record on April 16, 2014